BVES 抗体 (AA 251-300)
Quick Overview for BVES 抗体 (AA 251-300) (ABIN6743437)
抗原
See all BVES 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 251-300
-
特异性
- Human BVES
-
预测反应
- Percent identity by BLAST analysis: Dog, Bovine, Rabbit, Pig (100%).
-
纯化方法
- Immunoaffinity purified
-
免疫原
-
Synthetic peptide located between aa251-300 of human BVES (Q8NE79, NP_009004). Percent identity by BLAST analysis: Human, Chimpanzee, Gorilla, Gibbon, Monkey, Marmoset, Mouse, Rat, Elephant, Panda, Dog, Bovine, Bat, Rabbit, Horse, Pig, Opossum, Guinea pig, Turkey, Zebra finch, Sparrow, Chicken (100%), Galago, Platypus, Stickleback, Zebrafish (92%), Xenopus (85%).
Type of Immunogen: Synthetic peptide
-
-
anti-Blood Vessel Epicardial Substance (BVES) (AA 262-360) antibody
BVES 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 3F7 unconjugated
anti-Blood Vessel Epicardial Substance (BVES) (AA 241-360) antibodyBVES 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Blood Vessel Epicardial Substance (BVES) (AA 241-360) antibodyBVES 适用: 人 ELISA, IF 宿主: 兔 Polyclonal unconjugated
anti-Blood Vessel Epicardial Substance (BVES) (AA 262-360) antibodyBVES 适用: 人 WB, ELISA 宿主: 小鼠 Polyclonal unconjugated
anti-Blood Vessel Epicardial Substance (BVES) (AA 313-342), (C-Term) antibodyBVES 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal RB32739 unconjugated
anti-Blood Vessel Epicardial Substance (BVES) (AA 312-342), (C-Term) antibodyBVES 适用: 人 WB, EIA 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
Approved: WB (0.2 - 1 μg/mL)
Usage: Western Blot: Suggested dilution at 1 μg/mL in 5 % skim milk / PBS buffer, and HRP conjugated anti-Rabbit IgG should be diluted in 1: 50,000 - 100,000 as secondary antibody. -
说明
-
Target Species of Antibody: Human
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Distilled water
-
浓度
- Lot specific
-
缓冲液
- Lyophilized from PBS with 2 % sucrose
-
注意事项
- Avoid repeat freeze-thaw cycles.
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
Long term: -20°C, the use of 50% glycerol is recommended if storing aliquots in -20°C for long term use (up to 1 year)
Short term (less than 1 week): 4°C. Avoid freeze-thaw cycles.
-
-
-
